proteinbind
b
ioactiv
molecul
start
point
futur
drug
case
identifi
optim
two
clearli
separ
step
first
small
molecul
synthes
chemic
isol
natur
sourc
hen
biochem
properti
investig
bioassay
figur
step
repeat
iter
optim
processa
ccordingli
classic
process
lead
discoveri
character
strict
separ
gener
chemic
librari
screen
biolog
activ
aproteinbas
cellular
assay
last
two
decad
h
owev
na
ltern
concept
drug
discoveri
emerg
aim
integr
chemic
synthesi
bioassay
approach
exploit
molecular
recognit
reactiv
smallmolecul
fragment
protein
assembl
chemic
ligand
identif
bioactiv
fragment
combin
herefor
enomin
proteintempl
fragment
ligat
proteintempl
fragment
ligat
attract
altern
classic
drug
discoveri
sever
reason
combin
chemic
synthesi
bioassay
one
step
consider
confin
effort
chemic
synthesi
activ
fragment
combin
thu
sh
ighli
effici
save
time
money
energi
chemic
resourc
small
librari
af
ew
hundr
housand
reactiv
fragment
requir
cover
relev
chemic
space
test
huge
number
potenti
fragment
combin
fragment
ligat
productsm
oreov
f
ragment
ligat
enabl
detect
lowaffin
fragment
patial
resolv
protein
bind
site
sinc
bind
reactiv
primari
fragment
protein
probe
amplifi
bind
asecondari
fragment
ap
recis
defin
locat
review
present
current
state
futur
potenti
proteintempl
fragment
ligat
drug
discoveryfor
purpos
propos
acomprehens
definit
proteintempl
fragment
ligat
chemic
reaction
two
small
molecul
fragment
util
proteinssurfac
acatalyst
acceler
format
protein
ligand
increas
bind
affin
defin
proteintempl
fragment
ligat
definit
encompass
revers
irrevers
ligat
reactionsw
ec
onsid
combin
coverag
reaction
type
af
it
approach
templat
ligat
share
biophys
principl
pose
challeng
detect
product
nd
contribut
excel
exampl
drug
discoveri
processm
oreov
definit
creat
ac
lear
distinct
templat
fragment
ligat
catalyt
transform
exert
protein
similar
turnov
enzym
substratesr
emark
p
roteintempl
fragment
ligat
reaction
follow
definit
establish
mode
action
sever
clinic
admit
drug
suggest
reaction
inde
proceed
effici
physiolog
conditionsf
exampl
antiparkinson
drug
carbidopa
bind
enzym
dopad
ecarboxylas
react
cofactor
pyridox
phosphat
form
ahydrazon
activ
inhibitor
figur
likewis
anticonvuls
drug
vigabatrin
react
ap
roteintempl
mode
cofactor
gabat
ransaminas
form
ichael
acceptor
intermedi
w
hich
lead
irrevers
inhibit
enzym
figur
exampl
proteintempl
fragment
ligat
anovel
concept
support
drug
discoveri
help
improv
efficaci
protein
ligand
proteintempl
fragment
ligat
chemic
reaction
small
molecul
fragment
util
aproteinss
urfac
areact
vessel
catalyzeth
format
aprotein
ligand
increas
bind
affinityt
approach
xploit
molecular
recognit
reactiv
smallmolecul
fragment
protein
ligand
assembl
identif
bioactiv
fragment
combinationsinthi
way
chemic
synthesi
bioassayar
integr
one
singl
stept
review
discuss
biophys
basi
revers
irrevers
fragment
ligat
give
overview
avail
method
detect
proteintempl
ligat
productst
chemic
scope
recent
applic
well
futur
potenti
concept
drug
discoveri
review
proteintempl
fragment
ligat
admit
drug
found
selegilin
react
cofactor
fadi
nthe
depress
target
monoamin
oxidas
isoniazid
react
nad
mycobacterium
tuberculosi
catalas
fragment
ligat
driven
thermodynam
interact
fragment
protein
section
consid
biophys
basi
proteintempl
fragment
ligat
highlight
conceptu
potenti
method
special
emphasi
given
detect
product
fragment
ligat
reaction
amajor
gener
challeng
fragment
ligat
assay
section
section
give
overview
chemic
reaction
use
far
templat
ligat
also
discuss
possibl
futur
extens
reaction
set
revers
reaction
studi
context
dynam
coval
chemistri
irrevers
reaction
also
denomin
targetguid
synthesi
tg
treat
togeth
sb
oth
reaction
categori
deliv
exampl
templat
fragment
ligat
mani
case
difficult
categor
one
reaction
unambiguouslyr
epres
recent
applic
templat
ligat
fragmentbas
drug
discoveri
report
section
thu
demonstr
far
method
develop
datef
inal
n
section
ew
ill
discuss
current
state
proteintempl
fragment
ligat
consid
strength
method
requir
succeed
thec
omplementar
method
classic
ligand
screen
fragmentbas
method
consid
therebi
lead
outlook
relev
develop
proteintempl
fragment
ligat
futur
drug
discoveri
proteintempl
fragment
ligat
protein
serv
acatalyst
assembl
protein
ligand
protein
mike
jaegl
ee
lin
wong
carolin
tauber
eric
nawrotzkya
phd
student
group
come
academ
background
chemistri
pharmaci
nd
molecular
biolog
univers
freiburg
mj
johor
bahru
taipei
seoul
elw
berlin
ct
leipzig
en
work
project
involv
proteintempl
reaction
variou
protein
target
includ
proteas
phosphatas
proteinprotein
interact
christoph
arkona
studi
biochemistri
leibniz
univers
hannov
join
group
asenior
scientist
finish
ap
hd
plant
biochemistri
mani
year
drug
develop
biotech
industri
photo
show
left
right
mike
jaegl
eric
nawrotzki
rademann
c
arolin
tauber
c
hristoph
arkona
ee
lin
wong
bind
smallmolecul
fragmentst
molecul
fragment
chemic
reactiv
link
coval
yield
fragment
combin
improv
bind
affin
biolog
activitiest
process
requir
ac
hemic
reactiv
ynamic
system
abl
adapt
molecular
level
format
andin
case
revers
reactionsrecleavag
coval
chemic
bond
evolv
hermodynam
favor
state
hu
furnish
optim
protein
ligandss
uch
adapt
system
consid
exampl
molecular
learn
term
learn
appli
describ
adapt
chemic
evolv
selfoptim
system
theaddit
free
bind
energi
drive
forc
proteintempl
fragment
ligat
figur
tw
fragment
bind
protein
independ
without
overlap
free
energi
bind
dg
dg
thel
ink
two
fragment
ar
evers
irrevers
chemic
reaction
form
alig
product
afre
bind
energi
dg
lig
dg
dg
x
w
x
repres
deviat
addit
bind
energiesprovid
coval
link
two
fragment
addit
x
obtain
fragment
combin
product
display
abind
affin
product
bind
affin
fragment
k
e
k
k
fore
xampl
wo
fragment
k
valu
result
af
ragment
ligat
product
mminfact
fragment
combin
also
strongli
superaddit
asaresult
addit
bind
energi
linker
entrop
gain
result
even
stronger
enhanc
bind
affin
likewis
link
two
fragment
reduc
bind
energi
ligat
product
addit
linker
contribut
unfavor
bind
thea
nalyt
detect
proteinbind
fragment
constitut
ajor
challeng
ignific
limit
develop
exploit
fragmentbas
method
drug
discoveryt
main
reason
detect
problem
low
affin
proteinbind
fragment
requir
high
fragment
concentr
gener
possibl
satur
detect
signal
assay
uch
fluoresc
anisotropi
satur
transfer
differ
std
nmr
high
protein
concentr
use
instead
satur
bind
smallmolecul
ligand
compar
fragmentbas
method
without
ligat
detect
problem
howev
ss
ignificantli
reduc
proteintempl
fragment
ligat
due
higher
affin
fragment
ligat
product
form
aresult
fragment
ligat
assay
principl
detect
even
lowaffin
fragment
would
identifi
fragment
assay
exampl
concentr
limit
gener
fragment
present
concentr
exceed
dissoci
constant
k
valu
afactor
least
trong
satur
detect
signal
measur
contrast
case
afrag
ligat
assay
c
oncentr
start
fragment
k
valu
typic
use
effect
partial
inhibit
satur
format
stronger
bind
ligat
product
although
detect
fragment
ligat
product
therebi
strongli
facilit
compar
singl
fragment
remain
ac
halleng
sever
reasonsa
st
ligat
product
possess
ah
igher
bind
affin
start
fragment
target
protein
format
autoinhibitori
amount
ligat
product
limit
strictli
concentr
protein
templatea
ar
esult
fragment
ligat
product
detect
astrong
background
excess
nonreact
fragment
challeng
aris
reactiv
fragment
fragment
ligat
assaysalthough
reactiv
fragment
use
dipolar
cycloaddit
reaction
truli
bioorthogon
sever
fragment
ligat
reli
electrophil
might
also
react
protein
nucleophil
reaction
partnersc
ontrol
experi
distinguish
effect
one
fragment
effect
af
ragment
combin
routin
conduct
avoid
interfer
reaction
assay
readout
addit
gener
recommend
hit
valid
use
independ
secondari
assay
detect
falseposit
hit
fragment
sever
classic
analyt
method
wide
appli
adapt
detect
templat
fragment
ligat
figur
studi
field
use
liquid
chromatographi
usual
combin
mass
spectrometri
lcm
exampl
pecif
method
nmr
spectroscopi
develop
addit
fragment
ligat
studi
xray
crystallographi
final
asapow
complement
detect
fragment
ligat
product
variou
bioassay
develop
recent
year
thed
etect
fragment
ligat
product
lcm
becom
substanti
easier
last
two
decad
rapid
develop
method
term
chromatograph
separ
sensit
mass
detector
detect
also
quantif
structur
elucid
ligat
product
facilit
use
extractedion
singleion
chromatographi
msm
techniquess
ome
limit
remain
howevera
chromatograph
separ
take
time
l
cm
detect
best
suit
irrevers
quasiirrevers
ligat
reaction
case
revers
form
ligat
product
heir
chemic
fixat
ac
hemic
reaction
ap
hs
hift
option
strategi
follow
exampl
nt
semin
report
huc
lehn
virtual
chemic
librari
unstabl
imin
ligat
product
convert
stabl
amin
chemic
reduct
ligat
reaction
asecond
limit
lcm
detect
aris
buffer
system
use
fragment
ligat
reactionsmani
buffer
ion
use
ligat
assay
interfer
detect
ligat
product
mass
detector
w
herea
buffer
salt
ammonium
formiat
acet
highli
compat
lcm
may
interfer
ligat
reaction
ad
reactiv
nucleophil
strong
excessinrec
year
detect
proteinbind
fragment
nativ
protein
ms
develop
atur
technolog
like
method
also
use
detect
fragment
ligat
product
nmr
spectroscopi
big
advantag
lc
monitor
ligat
reaction
directli
assay
solut
standard
nmr
spectroscopi
requir
high
mm
c
oncentr
fragment
ligat
product
volum
around
ml
chemic
analysi
l
arg
amount
protein
requir
therefor
method
applic
protein
avail
larg
quantiti
af
ew
experi
low
throughput
conduct
throughput
enhanc
mixtur
reactiv
fragment
employ
undergo
revers
c
oval
ligat
reaction
mixtur
denomin
dynam
combinatori
librari
dcl
dynam
coval
librari
principl
form
possibl
combin
avail
fragment
build
block
inth
case
n
complementari
reactiv
build
block
anumb
n
possibl
product
obtain
thep
rotein
templat
shift
equilibrium
favor
best
bind
thu
ost
stabil
ligat
product
detect
one
classic
analyt
method
sever
nmr
method
adapt
specif
detect
fragment
ligat
productsr
cowork
investig
hstd
nmr
spectroscopi
detect
hemithioacet
form
ap
roteintempl
reaction
aqueou
medium
figur
hstd
nmr
spectroscopi
ethod
exploit
select
transfer
proton
magnet
protein
revers
bound
ligand
use
identifi
bind
fragment
ad
cl
foraproof
concept
studi
bgalactosidas
select
target
protein
catalyz
hydrolysi
obgalactosid
contain
cystein
residu
activ
siteamixtur
five
thiol
two
aldehyd
employ
therebi
result
potenti
format
ten
hemithioacetalsitwa
demonstr
bind
strongli
target
enzym
four
thiol
strongli
enhanc
signal
aldehyd
std
spectrumpresum
format
hemothioacet
surprisingli
bind
two
sugar
could
suppress
addit
substrat
hu
suggest
addit
alloster
bind
site
fragmentss
ignific
inhibit
substrat
hydrolysi
could
confirm
one
thiolaldehyd
combin
also
suggest
format
hemithioacet
activ
inhibitor
anoth
applic
std
nmr
spectroscopi
publish
recent
hirsch
research
group
recent
bnmr
spectroscopi
appli
claridg
cowork
detect
fragment
ligat
product
see
figur
section
addit
ligandbas
nmr
spectroscopi
intens
applic
proteinbas
nmr
method
detect
proteinbind
fragment
protein
nmr
spectroscopi
use
mani
case
protein
produc
cand
nisotop
enhanc
nmr
signalsf
ragment
bind
observ
exampl
experi
perturb
chemic
shiftst
method
introduc
structureact
relationship
sar
nmr
spectroscopi
big
advantag
furnish
inform
bind
site
fragment
signal
nmr
spectra
assign
protein
structur
proteinbas
nmr
spectroscopi
also
av
aluabl
method
investig
fragment
ligat
reaction
although
could
find
applic
far
xray
crystallographi
found
broad
applic
fragmentbas
drug
discoveri
nd
attract
come
detail
structur
inform
reveal
fragmentprotein
complex
inform
extrem
help
design
fragment
combin
productss
ever
studi
far
use
protein
crystallographi
detect
fragment
ligat
product
ther
apid
parallel
detect
potent
fragment
ligat
product
form
proteintempl
reaction
final
realiz
introduct
bioactivitybas
assaysth
initi
strategi
denomin
dynam
ligat
screen
dl
revers
ligat
reaction
first
investig
dl
increas
sensit
ligand
detect
consider
nd
sitedirect
discoveri
low
affin
fragment
millimolar
k
valu
realiz
figur
bioactivitybas
detect
method
requir
minim
amount
protein
u
sualli
low
nanomolar
concentr
protein
suffici
conduct
use
standard
assay
equip
microtit
plate
autom
pipet
devic
use
handl
fragment
librariesi
ne
nzyme
assay
sensit
enhanc
catalyt
activ
figur
applic
hstd
nmr
spectroscopi
detect
proteintempl
format
hemithioacet
adynam
combinatorial
ibrari
enzymat
select
best
inhibitor
protein
target
result
rapid
turnov
mani
fluorogen
chromogen
substrat
moleculesf
luoresc
reson
energi
transfer
fret
also
use
detect
fragment
combin
reach
highest
sensit
primari
reactiv
fragment
ad
enzym
assay
ac
oncentr
result
nhibit
therebi
leav
easur
window
f
detect
enhanc
inhibit
addit
secondari
fragment
va
riou
bioassay
format
far
adapt
dynam
ligat
screen
figur
alreadi
describ
fluorogen
substrat
use
competit
assay
compet
fragment
ligat
product
enzymesb
ind
sitei
nt
assay
best
fragment
combin
result
strongest
inhibit
enzymat
reaction
figur
altern
substrat
construct
ar
eactiv
group
allow
fragment
ligat
ligat
fragment
increas
affin
substrat
target
protein
substrateenhanc
assay
figur
e
nabl
sitedirect
detect
proteinbind
fragment
secondari
bind
site
lead
acceler
turnov
substrat
competit
binder
also
detect
assay
format
special
case
reactiv
fluorogen
molecul
complet
inact
without
ligat
af
ragment
denomin
ap
resubstr
especi
sensit
detect
chemic
unstabl
ransient
ligat
product
hemiacet
hemithioacet
ethod
use
success
identif
secondarysit
bind
fragment
serin
proteas
protein
tyrosin
phosphatas
ptp
capabl
detect
specif
secondarysit
binder
astart
point
construct
ptpspecif
inhibitor
thep
rincipl
bioactivitybas
detect
fragment
ligat
product
also
extend
enzymat
assay
protein
bind
assay
thu
enabl
identif
ligand
nonenzymat
proteinbind
sitesp
roteinbind
assay
princip
conduct
either
homogen
solut
heterogen
attach
one
bind
partner
olid
phase
surfacea
homogen
proteinbind
assay
proteintempl
ligat
reaction
demonstr
use
fluoresc
polar
fp
also
known
fluoresc
anisotropi
detect
figur
forthi
assay
areact
proteinbind
peptid
fragment
label
af
luoro
angewandt
chemi
review
phoret
fp
ligand
nm
w
dissolv
ab
uffer
contain
target
protein
ac
oncentr
lead
l
igand
bindingt
hen
al
ibrari
fragment
screen
modul
fpt
assay
enabl
identif
compet
figur
nd
enhanc
fragment
figur
na
ingl
experi
templat
effect
exert
protein
quantifi
best
enhanc
fragment
combin
reduct
amin
label
fragment
best
enhanc
fragment
result
ap
icomolar
inhibitor
imilar
enzym
inhibit
assay
h
omogen
proteinbind
assay
fp
assay
conduct
highthroughput
equip
small
assay
volum
nd
low
nm
p
rotein
concentr
p
rovid
aligand
suffici
affin
avail
astart
point
labelfre
h
omogen
proteinbind
assay
attract
complement
detect
bioactiv
fragment
ligat
productsf
exampl
thermal
shift
assay
use
increasingli
detect
proteinligand
complex
ethod
monitor
defold
melt
protein
increas
temperatur
use
fluorophor
show
increas
fluoresc
come
contact
hydrophob
core
unfold
protein
fragment
bind
observ
ignific
enhanc
proteinsmelt
temperatur
free
bind
energi
ligand
even
thermodynam
inform
bind
fragment
reveal
isotherm
titrat
calorimetri
futur
studi
like
use
techniquealthough
requir
al
arg
quantiti
protein
conduct
low
throughput
heterogen
proteinbind
assay
appli
investig
proteinfrag
bind
method
labelfre
respect
fragment
h
owev
c
oval
immobil
label
affin
probe
biotin
requir
recent
bioactivitybas
detect
fragment
ligat
product
extend
protein
assay
even
complex
cellular
experi
ohkanda
cowork
report
intracellular
gener
inhibitor
protein
intracellular
oxim
ligat
figur
protein
involv
proteinprotein
interact
ppi
especi
difficult
inhibit
interact
larg
dynam
interact
surfac
disrupt
molecul
still
abl
penetr
cell
cellular
uptaket
author
realiz
reactiv
aldehyd
deriv
fusicoccin
fc
b
ind
ah
ydrophob
caviti
adjac
bind
site
peptid
contain
ah
ydroxylamin
functionalityt
hey
abl
demonstr
templat
format
ah
eterobival
ligat
product
potent
oxim
inhibitor
nvitro
presenc
protein
next
author
investig
intracellular
format
stabli
transform
flag
z
cell
line
hplc
analysi
show
format
cell
treat
w
hich
led
highest
cytotox
effect
contrast
chemic
synthes
inact
cell
p
ossibl
larg
molecular
size
imped
cellpenetr
properti
figur
thu
studi
demonstr
even
larg
molecul
potenti
modul
ppi
gener
intracellular
proteintempl
fragment
ligat
summari
consider
progress
made
detect
method
last
year
e
special
bioactivitybas
method
b
ut
also
classic
analyt
method
biophys
detect
strategi
h
facilit
identif
bioactiv
fragment
ligat
product
proteinbind
enzymat
cellular
assaysthi
develop
enabl
discoveri
exampl
templat
fragment
ligat
reaction
futur
therebi
contribut
success
applic
fragment
ligat
assay
numer
reaction
type
far
employ
templat
fragment
ligationsher
wewil
give
overview
reaction
type
focus
recent
addit
repertoir
give
outlook
extens
reason
expect
ap
ractic
viewpoint
degre
revers
ligat
reaction
import
criterium
affect
detect
isol
ligat
productst
hu
r
eaction
type
use
templat
fragment
ligat
categor
accord
revers
tabl
addit
heteronucleophil
aliphat
aromat
aldehydesketon
typic
repres
revers
ligat
reaction
equilibr
rapidli
aqueou
solut
aresult
low
activ
barriersther
howev
mark
differ
respect
revers
kinet
depend
react
nucleophil
hemiacet
hemithioacet
rapidli
form
water
aldehyd
alcohol
thiol
templat
fragment
ligat
although
isol
stabl
ligat
product
theform
hemiacet
hemithioacet
ligat
product
imped
competit
heteronucleophil
ah
igh
molar
excess
water
furnish
hydrat
altern
reaction
productsnevertheless
itcould
demonstr
use
nmr
spectroscopi
bioactivitybas
assay
aprotein
templat
abl
shift
ligat
equilibrium
thu
oenabl
identif
hemiacet
hemithioacet
ligat
product
contrast
hemiacet
full
acet
dithioacet
obtain
addit
two
alcohol
thiol
nucleophil
one
carbonyl
group
report
templat
ligat
product
expect
form
high
activ
barrier
carboc
intermedi
reaction
mani
templat
ligat
reaction
involv
nitrogen
nucleophil
react
carbonyl
electrophilest
addit
primari
amin
aldehyd
furnish
hemiamin
intermedi
w
hich
react
form
imin
imin
format
also
ap
rocess
equilibr
rapidli
requir
nonproton
amin
reactiv
thu
process
depend
pk
valu
amin
nucleophil
ph
valu
reaction
bufferi
mine
consider
stabl
hemiacet
e
special
form
aromat
amin
even
isol
case
one
consequ
increas
stabil
imin
equilibr
dynam
combinatori
librari
may
take
significantli
longer
equilibr
hemiacet
hemithioacetalst
stabil
aminealdehyd
ligat
product
enhanc
aldehyd
carri
acid
ahydrogen
atom
w
hich
allow
format
enaminesa
nother
possibl
chemic
fixat
imin
irrevers
reaction
exampl
r
educt
amin
yield
secondari
amin
thestabl
ligat
product
nitrogen
nucleophil
aldehyd
elev
case
hydroxylamin
h
ydrazin
acyl
hydrazid
theform
product
oxim
acyl
hydrazon
stabl
physiolog
ph
valu
isol
standard
procedur
uch
column
chromatographya
ccordingli
ligat
reaction
equilibr
slowli
anilin
ad
acatalyst
format
hydrazin
oxim
altern
equilibr
acyl
hydrazon
acceler
addit
acid
ligat
heteronucleophil
aldehyd
await
investig
forexampl
thiol
ad
imin
furnish
n
sacet
al
igat
equilibrium
possibl
shift
interact
aprotein
templat
bioactiv
data
obtain
investig
ap
resubstr
suggest
trimer
complex
aldehyd
mine
nd
thiol
tronger
affin
protein
target
express
ar
educ
k
valu
increas
turnov
enzym
substrat
likewis
observ
superaddit
bind
inhibit
peptid
aldehyd
amin
quantifi
fp
assay
interpret
format
thioamin
product
mannich
base
aspeci
form
stabl
amin
also
expect
suitabl
proteintempl
reaction
atop
current
investig
group
templat
fragment
ligat
involv
addit
heteronucleophil
celectrophil
aldehydest
hiomichael
addit
report
sever
case
nd
product
usual
isol
even
though
reaction
revers
product
favor
retroaddit
belimin
alkyl
usual
truli
irrevers
ligat
nm
ost
case
thiolat
employ
nucleophil
highest
reactiv
aliphat
halogenid
e
poxid
rs
ulfon
use
electrophil
studi
suggest
altern
celectrophil
use
proteintempl
reactionsfor
exampl
nucleophil
substitut
electronpoor
aryl
moieti
could
interest
extens
reaction
repertoir
boric
acid
boron
acid
use
altern
electrophilest
use
diol
bisnucleophil
furnish
boron
ester
ligat
product
limit
stabil
popular
exampl
revers
reaction
furnish
stabl
product
isol
disulfid
format
disulfid
exchang
reaction
use
thiolat
reactiv
nucleophil
slightli
basic
nonreduc
condit
asimilar
exchang
reaction
thiolat
report
thioester
exchang
reaction
c
cb
ondform
reaction
special
interest
templat
ligat
st
hey
extend
choic
divers
access
ligat
product
considerablyf
ew
exampl
report
date
cowork
describ
ar
evers
templat
henryaldol
addit
nitroalkan
aldehyd
n
form
bestbound
secondari
alcohol
prefer
acyl
lipas
protein
target
assay
although
report
templat
aldol
reaction
yet
publish
reaction
type
highli
suitabl
fragment
ligat
chemistri
consid
detail
literatur
aldol
reaction
water
mild
reaction
condit
likewis
ddition
cyanid
anion
isocyanid
report
water
suggest
passerini
ugi
reaction
might
highli
suitabl
proteintempl
reactionst
appli
ond
format
alken
alkyn
metathesi
reaction
far
demonstr
ligat
reaction
water
classic
exampl
irrevers
templat
reaction
report
dipolar
cycloaddit
reaction
includ
azidealkyn
ligat
furnish
hemiacet
b
hemithioacet
c
acet
thioacet
e
n
sacet
f
imin
g
hydrazon
g
acylhydrazon
h
oxim
boron
j
disulfid
k
thioester
l
alken
metathesi
alkyn
metathesi
n
nitroaldol
alkyl
p
amid
sulfonylazid
thioacid
q
r
addit
ring
open
amid
amin
activ
ester
nd
sulfonylazidethioacid
ligat
provid
sulfonylamid
ac
yclic
intermedi
clear
numer
ligat
base
cycloaddit
reaction
may
also
succeed
besid
cycloaddit
reaction
h
owev
irrevers
ligat
yet
investig
much
futur
extens
necessari
provid
ligat
product
cover
alarg
part
biolog
relev
chemic
spacei
ng
ener
chemoselect
reaction
water
requir
asuccess
ligat
ideal
reaction
provid
alink
react
fragment
support
bind
least
interfer
fore
xampl
structur
analysi
world
drug
index
collect
molecul
report
bioactiv
reveal
amid
linkag
privileg
linker
bioactiv
compound
thu
aproteintempl
amid
reaction
consid
especi
use
extens
fragment
ligat
repertoirev
eri
recent
first
backgroundfre
proteintempl
amid
reaction
discov
reaction
type
could
consider
extend
opportun
fragment
ligat
reaction
abl
connect
fragment
without
al
inker
remain
product
crosscoupl
reaction
reaction
form
heterocycl
connect
two
fragment
instead
ac
lassic
linker
moieti
defin
fragment
ligat
reaction
e
xplain
biophys
background
use
detect
strategi
nd
underli
chemic
transform
w
ea
go
focu
applic
concept
discoveri
optim
protein
ligandsw
ew
ill
start
revers
ligat
reaction
proceed
irrevers
one
mani
first
applic
revers
emplat
fragment
ligat
report
dynam
combinatori
librari
dcl
ar
ecent
repres
exampl
line
research
highlight
studi
hirsch
cowork
theauthor
employ
endothiapepsin
atarget
model
enzym
aspart
acid
proteasesn
ine
hydrazid
one
bisaldehyd
use
form
adynam
librari
deriv
two
fragment
hit
bind
adjac
bind
pocket
endothiapepsin
figur
eas
analysi
two
sublibrari
form
consist
four
five
hydrazidesr
eversedphas
hplc
lcm
employ
analyz
templat
format
bisacylhydrazon
ligat
product
presenc
endothiapepsin
potenti
differ
bisacylhydrazon
monoacylhydrazon
nli
ossibl
fragment
combin
show
signific
amplif
hplc
signal
presenc
endothiapepsin
templatet
wo
found
combin
w
ere
synthes
test
af
luorescencebas
biochem
assayb
oth
report
activ
best
inhibitor
show
increas
potencyc
ompar
start
fragment
thu
illustr
uccess
exampl
emplat
threefrag
ligat
reaction
thea
uthor
demonstr
studi
unlik
fragment
optim
method
fragment
grow
merg
templat
fragment
ligat
especi
sensit
discov
combin
fragment
superaddit
w
ligand
effici
maintain
improv
approach
challeng
lay
preserv
bind
mode
fragment
find
aw
ellfit
linker
provid
addit
interact
target
despit
posit
result
studi
also
demonstr
limit
dcl
name
tediou
analysi
complex
combinatori
mixtur
limit
dynam
reaction
deliv
nondruglik
product
acylhydrazon
figur
proteintempl
fragmentlig
use
adynam
combinatorial
ibrari
isophthalaldehyd
nine
hydrazid
form
bisacylhydrazon
bi
model
protein
endothiapepsin
equilibr
dcl
format
potenti
inhibitor
bii
hplc
analysi
show
format
bisacylhydrazon
amplifi
presenc
enzym
biii
bind
mode
purpl
cyan
determin
xray
crystallographi
pdb
kup
respect
c
best
compound
exhibit
improv
potenc
higher
ligand
efficiencyc
ompar
start
fragment
the
ame
limit
display
studi
claridg
cowork
appli
bnmr
spectroscopi
detect
serin
proteas
inhibitor
adcl
foraproofofconcept
studi
achymotrypsin
act
recruit
amodel
enzym
nd
boron
acid
ligat
ad
sugar
molecul
form
improv
enzym
inhibitorst
format
ternari
complex
enzym
boron
acid
sugar
diol
monitor
bnmr
hwaterlogsi
waterligand
observ
gradient
spectroscopi
find
encourag
group
schofield
claridg
appli
nativ
mass
spectrometri
detect
hit
ad
cl
revers
form
boron
ester
identifi
inhibitor
prolyl
hydroxylas
domain
isoform
enzym
oxygenas
famili
figur
fe
ii
contain
oxygenas
help
regul
human
hypox
respons
thu
make
excel
drug
target
treatment
anemia
ischemiarel
diseas
experi
aheterocycl
ironbind
boron
acid
fragment
incub
sever
pool
diol
ligand
subsequ
analyz
nativ
mst
bestbind
fragment
combin
identifi
shift
protein
mass
convert
stabl
boronfre
inhibitor
use
suzuki
crosscoupl
reaction
w
hich
result
inhibitor
enzym
activ
nanomolar
rangeth
result
fragment
ligat
assay
valid
anoth
studi
use
hnmr
base
method
theteth
approach
aclass
exampl
revers
templat
fragment
ligat
use
disulfid
exchang
reaction
method
exploit
revers
disulfid
exchang
reaction
atur
engin
cystein
residu
protein
surfac
ad
isulfidecontain
smallmolecul
fragment
solut
develop
erlanson
group
use
socal
extend
made
approach
even
applic
fragment
combin
reaction
report
inhibitor
screen
target
aurora
kinas
figur
first
step
introduc
ac
ystein
residu
near
atp
bind
siten
ext
extend
synthes
contain
two
disulfidecontain
residu
ad
iaminopyridin
group
w
hich
known
bind
purin
bind
site
one
disulfid
residu
abl
react
exchang
introduc
cystein
residu
one
abl
bind
econdari
disulfid
fragment
secondari
fragment
abl
interact
adapt
region
protein
adjac
extend
athermodynam
stabil
disulfid
bond
form
stabil
complex
subsequ
detect
ms
measur
modif
proteinsm
assi
nt
heir
experi
alibrari
contain
roughli
disulfidecontain
fragment
screen
pool
compound
w
hich
result
identif
sever
fragment
combinationsafew
modif
correspond
fragment
led
format
astabl
inhibitor
affin
micromolar
rangeasimilar
approach
success
appli
anoth
phosphoinositidedepend
protein
attach
extend
irrevers
alkyl
reaction
dynam
ligat
screen
introduc
overcom
detect
limit
combinatori
method
dcl
thef
irst
bioactivitybas
detect
dynam
form
fragment
ligat
product
demonstr
figur
schemat
represent
gener
boron
acidest
lead
use
proteindirect
dynam
combinatori
librari
contain
diol
boron
acid
b
identif
potent
boron
ester
conjug
use
ab
oron
acid
scaffold
ligand
lead
discoveri
first
second
gener
stabl
analoguest
hat
inhibit
nanomolar
rang
sar
coronaviru
main
proteas
sarscov
pro
figur
sarscov
pro
av
irusencod
cystein
proteas
essenti
replic
viru
insid
infect
host
cellsi
nhibitor
target
pro
herefor
relev
potenti
antivir
sinc
proteas
possess
defin
bind
pocket
side
chain
peptid
itwa
possibl
develop
ap
eptid
aldehyd
inhibitor
posit
electrophil
aldehyd
precis
activ
site
proteasedynam
ligat
screen
afrag
librari
divers
nucleophil
reveal
sever
fragment
hit
target
pocket
enzym
k
valu
millimolar
ranget
best
fragment
hit
convert
correspond
aldehyd
fragment
assay
enhanc
inhibit
amin
librari
herebi
provid
asecondari
hit
fragment
adjac
pocket
enzymesb
ind
siteo
nli
two
iter
dynam
ligat
screen
start
apeptid
inhibitor
result
select
two
millimolaract
smallmolecul
fragment
nd
coval
combin
fragment
reduct
amin
reveal
entir
nonpeptid
inhibitor
sarscov
pro
k
valu
mm
exampl
bioactivitybas
dynam
ligat
assay
summar
tabl
caspas
play
essenti
role
execut
phase
cell
apoptosi
therefor
ap
otenti
drug
target
traumat
brain
injuri
amyotroph
later
sclerosi
well
alzheim
parkinsonsdiseaset
protein
test
ananomolar
fluorophorelabel
peptidyl
ketoaldehyd
inhibitor
atot
fragment
includ
nucleophil
primari
amin
microtit
plate
byappli
fp
bind
assay
describ
aboveweobserv
chang
fragment
test
fragment
led
lower
fp
signal
neg
cooper
fragment
evok
asignificantli
stronger
fp
signal
posit
cooper
control
fragment
confirm
competit
inhibitor
k
mmt
best
cooper
bind
fragment
b
link
coval
start
ligand
reduct
amin
therebi
result
apot
inhibitor
k
valu
pm
dynam
ligat
assay
implement
secondarysit
screen
four
close
relat
protein
tyrosin
phosphatas
ptp
human
p
mycobacteri
mptpa
gener
develop
specif
ptp
inhibitor
consid
amajor
challeng
rais
doubt
druggabl
physiolog
relev
class
enzymesb
yu
sing
figur
ateth
approach
use
ad
ynamic
xtender
appli
screen
fragment
bind
aurora
kinas
angewandt
chemi
review
phenyl
phosphat
electrophil
ptp
substrat
pecif
secondarysit
bind
fragment
could
identifi
ptp
al
ibrari
primari
aminest
specif
secondari
site
binder
detect
use
dynam
substrat
enhanc
assay
see
figur
activ
fragment
form
al
igat
product
ptp
substrat
result
ahigh
stabil
enzymesubstr
complex
alow
k
valuethi
lead
amplifi
releas
phosphat
ion
w
hich
determin
alachit
green
assayr
eplac
phenyl
phosphat
substrat
anoncleav
phosphotyrosin
mimet
coval
link
select
mptpaspecif
amin
fragment
furnish
inhibitor
protein
tyrosin
phosphatas
mptpa
mycobacterium
tuberculosi
w
ith
activ
three
ptpst
result
suggest
secondsit
target
ptp
enabl
develop
select
ptp
inhibitor
dynam
ligat
screen
extend
toward
aspart
proteas
time
employ
af
luoresc
reson
energi
transfer
fret
assay
ap
eptid
aldehyd
use
adirect
probe
identifi
activesit
bind
fragment
aspart
proteas
bsecretas
enzym
known
main
culprit
aggreg
amyloidbpeptid
w
hich
ajor
patholog
hallmark
alzheimersdiseas
ad
thu
consider
effort
made
discov
inhibitor
potenti
therapeut
treatment
adi
nstead
revers
hemithioacet
format
aldehyd
hydrat
form
bind
catalyt
aspart
acid
dyad
format
ah
ydrogen
bond
dynam
ligat
peptid
aldehyd
amin
nucleophil
revers
yield
imin
product
thep
eptid
aldehyd
w
hich
serv
ac
hemic
reactiv
inhibitor
cri
reveal
ac
ompetit
inhibitort
identifi
aminophenyl
coumarin
fragment
use
astart
point
hit
optim
al
ow
micromolar
k
mm
b
inhibitor
develop
anoth
applic
bioactivitybas
detect
report
recent
aspart
proteas
endothiapepsin
recent
applic
revers
proteintempl
fragment
ligat
extend
toward
discoveri
irrevers
inhibitor
enterovir
proteas
figur
epoxyaldehyd
amodifi
partial
structur
known
inhibitor
cystein
proteas
aweak
irrevers
inhibitor
proteas
coxsacki
viru
w
test
al
ibrari
primari
amin
aminopyrazolon
discov
af
ragment
hit
led
asuperaddit
inhibit
proteas
coval
modif
enzym
addit
fragmentsi
ter
optim
ligat
product
final
led
submicromolar
b
roadspectrum
inhibitor
enterovir
proteas
w
ith
acceler
protein
deactiv
rate
signific
crossreact
nonvir
proteas
earli
studi
area
irrevers
proteintempl
fragment
ligat
conduct
sharpless
group
denomin
kinet
targetguid
synthesist
hey
use
dipolar
cycloaddit
azid
alkyn
situ
click
reaction
templat
protein
acetylcholinesteras
ach
arget
treatment
alzheim
diseas
af
ollowup
studi
method
appli
target
goal
identifi
synthes
af
ragment
combin
occupi
activ
center
peripher
bind
site
figur
astart
point
establish
ach
inhibitor
tacrin
use
bind
activ
center
enzym
tacrin
modifi
introduc
azid
functionalitya
compound
collect
termin
acetylen
compos
peripher
site
bind
fragment
test
detect
format
dipolar
cycloaddit
first
lcm
result
confirm
proteinstempl
effect
ligat
reaction
bound
fragmentso
nli
presenc
enzym
syn
triazol
form
littl
background
reaction
confirm
reaction
singl
fragment
pair
author
turn
attent
reaction
contain
mixtur
acetylen
compoundsinde
protein
templat
induc
format
highli
potent
fragment
combin
dissoci
constant
low
picomolar
even
femtomolar
rang
azidealkyn
ligat
also
appli
protein
target
fore
xampl
format
aknown
nanomolar
inhibitor
hiv
proteas
contain
antisubstitut
acceler
presenc
figur
developmento
fafragmentbas
nonpeptid
sarscov
main
proteas
inhibitor
start
ap
eptid
aldehyd
dynam
ligat
screen
alibrari
nucleophil
yield
amin
bind
subpocket
proteas
amin
convert
electrophil
w
hich
furnish
asecondari
hit
fragmenti
nthe
next
iter
reductivea
minat
fragment
best
amin
hit
secondari
screen
yield
inhibitor
enzym
case
reaction
consider
slower
report
picofemtomolar
ach
inhibitor
nd
time
ac
lear
background
reaction
furnish
syntriazol
observ
proteintempl
azidealkyn
click
reaction
also
success
appli
abl
tyrosin
kinas
thef
ukas
research
group
demonstr
templat
synthesi
function
mimet
domain
inhibit
growth
cancer
cell
vitro
obtain
best
inhibitor
templat
reaction
azid
alkyn
fragment
crucial
exclud
even
tini
amount
copper
ion
reaction
theg
roup
miyata
finn
report
situ
synthesi
inhibitor
histon
deacetylas
alkyn
fragment
bear
ah
ydroxam
azid
fragment
surprisingli
form
ligat
product
best
inhibitor
far
contain
antitriazol
instead
activ
syntriazol
ad
etail
scrutini
result
reveal
reaction
contain
trace
cu
ion
w
hich
bound
metalbind
site
suffici
catalyz
reaction
lessfavor
cycloaddit
product
addit
azidealkyn
ligat
dipolar
cycloaddit
also
investig
reaction
thioacid
sulfonylazid
fragment
provid
acylsulfonamid
via
ac
yclic
intermedi
c
onstitut
especi
success
exampl
denomin
sulfoclick
reaction
manetsch
group
demonstr
proteintempl
irrevers
ligat
reaction
ap
articularli
challeng
target
ppi
domain
bclx
l
theinteract
bclx
l
peptid
ac
rucial
step
regul
apoptosi
program
cell
death
inhibitor
interact
might
potent
anticanc
agentsi
n
ascreen
new
modul
bclx
l
protein
use
atempl
proteintempl
sulfoclick
reaction
ulfonylazid
hioacid
fragment
figur
could
shown
format
micromolar
bclx
l
inhibitor
proceed
aproteintempl
reaction
less
inhibitor
review
wwwangewandteorg
form
without
protein
block
bind
site
peptid
addit
inact
mutat
peptid
effect
proteintempl
irrevers
fragment
ligat
recent
establish
format
amid
bond
amid
reaction
one
relev
fragment
linkag
bioactiv
compound
clinic
admit
drug
figur
ac
ollect
activ
ester
cover
ab
road
rang
chemic
reactiv
incub
nd
protein
factor
xa
adrug
target
blood
coagul
cascad
od
iscov
condit
proteintempl
amid
reactionst
wo
activ
ester
fragment
phenyl
ester
trifluoroethyl
ester
display
aclear
proteintempl
amid
substrat
competit
assay
lcm
nd
afford
nanomolar
inhibitor
two
weakli
bind
fragment
millimolar
affinitiesextractedion
chromatographi
aq
tofd
etector
use
quantifi
progress
proteintempl
format
inhibitor
reaction
trifluoroethyl
ester
proceed
without
detect
background
reaction
autoinhibit
atur
concentr
nm
free
inhibitor
theinhibitor
display
aremark
superaddit
enhanc
free
bind
energi
k
valu
nm
instead
mm
addit
case
proven
result
rel
decreas
entropi
bind
fragment
linkingt
proteininhibitor
complex
crystal
obtain
highresolut
structur
allow
author
ration
templat
amid
reaction
steric
mechanist
detail
figur
discoveri
irrevers
inhibitor
coxsacki
viru
proteas
use
revers
proteintempl
fragment
ligat
nucleophil
amin
fragment
bind
pocket
enzym
revers
form
af
ragment
ligat
product
biselectrophil
warhead
b
next
epoxid
open
attack
cystein
side
chain
activ
site
detect
lcm
c
ligat
product
display
asuperaddit
inhibitori
effect
fret
assay
optim
potent
broadband
inhibitor
enterovir
rhinovir
proteas
figur
developmentofach
inhibitor
proteintempl
fragment
ligat
reaction
ach
inhibitor
tacrin
modifi
azid
function
act
anchor
molecul
activ
site
protein
mixtur
variou
acetylen
ad
templat
reaction
furnish
two
highli
potent
proteintempl
fragment
ligat
establish
altern
complementari
rout
access
bioactiv
protein
ligand
recent
yearss
ignific
progress
realiz
sever
frontsi
mprove
special
analyt
bioanalyt
method
contribut
ab
road
implement
ap
rofound
understand
method
thechem
scope
ligat
figur
templat
format
sulfonamid
inhibitor
protein
bclx
l
fragment
sulfonylazid
thioacid
refer
compound
obtain
chemic
synthesi
b
templatedr
eaction
fragment
incub
presenc
target
protein
b
clx
l
serv
atempl
format
c
backgroundr
eaction
f
ragment
incub
without
bclx
l
lead
small
amount
product
block
bclx
l
bind
site
peptid
suppress
product
formation
mutat
alow
affin
toward
bclx
l
herebi
lead
inhibit
templat
fragmentl
igat
reaction
figur
proteintempl
amid
activ
ester
f
urnish
nanomolar
inhibitor
protein
factor
xa
proteintempl
backgroundfre
reaction
demonstr
ab
ioactivitybas
assay
autoinhibitori
kinet
inhibitorf
ormat
proven
qtofm
crystal
structur
proteininhibitor
complex
enabl
pathway
templat
reaction
model
review
wwwangewandteorg
reaction
continu
extend
extens
reaction
deliv
templat
fragment
ligat
product
expect
review
biophys
background
underli
chemistri
actual
applic
method
consid
strength
limit
final
give
outlook
futur
possibl
develop
techniqu
part
drug
discoveri
process
theb
iggest
advantag
proteintempl
fragment
ligat
compar
fragmentbas
method
enabl
sitedirect
spatial
resolv
identif
fragment
bind
ap
recis
defin
protein
pocket
fragmentbas
method
f
exampl
xray
crystallographi
nmrbase
method
lso
deliv
structur
inform
ligand
bind
h
owev
use
screen
specif
one
bind
site
sitedirect
fragment
detect
realiz
structur
defin
bind
reactiv
start
fragment
the
econd
major
advantag
proteintempl
fragment
ligat
assay
sensit
caus
super
addit
bind
enhanc
ligat
fragmentsa
ar
esult
fragment
ligat
assay
identifi
fragment
detect
fragmentbas
discoveri
method
consider
higher
fragment
protein
concentrationsthu
method
may
provid
protein
ligand
altern
structur
improv
ligand
efficienciesa
sathird
advantag
p
roteintempl
fragment
ligat
practic
econom
benefit
mainli
aris
integr
synthesi
fragment
combin
detect
bioactiv
one
stepasaresult
effort
resourc
requir
chemic
synthesi
bioactiv
ligand
reduc
consider
bioactiv
fragment
combin
need
resynthes
structur
function
valid
wherea
classic
highthroughput
screen
use
larg
librari
druglik
molecul
cover
chemic
space
f
ragment
ligat
screen
need
small
librari
reactiv
fragment
sampl
chemic
space
potenti
fragment
combin
one
gener
requir
fragment
ligat
assay
need
areact
start
fragment
could
problemat
suitabl
ligand
atarget
protein
known
case
c
omplementari
method
classic
screen
structurebas
design
indispens
provid
start
point
fragment
ligat
anoth
major
requir
proteintempl
ligat
assay
avail
ligat
reaction
cover
relev
chemic
space
compat
condit
protein
assayalthough
shown
section
number
chemic
reaction
adapt
fragment
ligat
screen
constantli
grow
continu
research
effort
need
make
privileg
druglik
fragment
linkag
access
ligat
assaysi
np
articular
c
cb
ondform
reaction
format
heterocycl
nd
direct
connect
cyclic
fragment
w
hich
often
construct
crosscoupl
reaction
need
investig
thec
ritic
evalu
show
proteintempl
fragment
ligat
current
consid
ab
roadli
applic
method
contribut
modern
drug
discoveri
process
complement
establish
success
method
specif
virtu
requir
patial
resolv
sitedirect
screen
high
sensit
identif
novel
fragment
well
chemic
develop
known
protein
ligand
futur
research
show
specif
advantag
method
abl
provid
clinic
candid
improv
propertiest
ultim
signific
proteintempl
fragment
ligat
depend
extent
contribut
fulfil
promis
fragmentbas
drug
discoveri
f
ind
better
drug
high
potenc
specif
nd
fewer
offtarget
relat
side
effectsm
ost
like
proteintempl
fragment
ligat
contribut
goal
close
collabor
fragmentbas
classic
lead
discoveri
approachesb
eyond
practic
success
method
drug
discoveri
process
proteintempl
ligat
reaction
also
potent
attract
research
train
tool
teach
us
partial
structur
olecul
interact
addit
creat
highaffin
protein
ligandst
hrough
method
help
us
understand
molecular
recognit
make
molecul
life
work
molecular
evolut
proceed
